Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survival
Abstract Adenomyoepithelioma of the breast (AME) is a rare, biphasic tumor characterized by the coexistence of both epithelial and myoepithelial cell components, which can present as benign, atypical, or malignant forms. We present a 50-year-old female diagnosed with malignant AME (M-AME) exhibiting...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02120-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849389944860049408 |
|---|---|
| author | Hung-Liang Pai Wei-Ting Hsu Chia-Chi Chang Ming-Hsin Yeh |
| author_facet | Hung-Liang Pai Wei-Ting Hsu Chia-Chi Chang Ming-Hsin Yeh |
| author_sort | Hung-Liang Pai |
| collection | DOAJ |
| description | Abstract Adenomyoepithelioma of the breast (AME) is a rare, biphasic tumor characterized by the coexistence of both epithelial and myoepithelial cell components, which can present as benign, atypical, or malignant forms. We present a 50-year-old female diagnosed with malignant AME (M-AME) exhibiting low-positive estrogen receptor (ER) expression of 5%, alongside pathogenic HRAS Q61R and PIK3CA H1047R mutations. Immunohistochemistry showed low-positive ER, negative progesterone receptor (PR), HER2, and a high Ki-67 index. Sanger sequencing identified HRAS and PIK3CA mutations. The tumor was staged as pT2N0M0 with no lymph node involvement. The patient underwent partial mastectomy, followed by sentinel lymph node biopsy, which showed no metastasis. Postoperatively, she received four cycles of adjuvant chemotherapy, followed by radiotherapy. The patient achieved disease-free survival at 10 months with no recurrence on imaging. This case highlights the challenges of ER classification in M-AME and highlights the significance of molecular profiling in guiding treatment. The concurrent HRAS and PIK3CA mutations suggest potential targeted therapies, emphasizing the importance of a multidisciplinary approach. Further research is needed to establish standardized treatment guidelines for M-AME. |
| format | Article |
| id | doaj-art-d57027d8c44f4ef5a1e2e712960b3d36 |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-d57027d8c44f4ef5a1e2e712960b3d362025-08-20T03:41:49ZengSpringerDiscover Oncology2730-60112025-03-011611610.1007/s12672-025-02120-2Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survivalHung-Liang Pai0Wei-Ting Hsu1Chia-Chi Chang2Ming-Hsin Yeh3Department of Medicine, Chung Shan Medical UniversityDepartment of Medicine, Chung Shan Medical UniversityDepartment of Medicine, Chung Shan Medical UniversityDivision of Breast Surgery, Department of Surgery, Chung Shan Medical University HospitalAbstract Adenomyoepithelioma of the breast (AME) is a rare, biphasic tumor characterized by the coexistence of both epithelial and myoepithelial cell components, which can present as benign, atypical, or malignant forms. We present a 50-year-old female diagnosed with malignant AME (M-AME) exhibiting low-positive estrogen receptor (ER) expression of 5%, alongside pathogenic HRAS Q61R and PIK3CA H1047R mutations. Immunohistochemistry showed low-positive ER, negative progesterone receptor (PR), HER2, and a high Ki-67 index. Sanger sequencing identified HRAS and PIK3CA mutations. The tumor was staged as pT2N0M0 with no lymph node involvement. The patient underwent partial mastectomy, followed by sentinel lymph node biopsy, which showed no metastasis. Postoperatively, she received four cycles of adjuvant chemotherapy, followed by radiotherapy. The patient achieved disease-free survival at 10 months with no recurrence on imaging. This case highlights the challenges of ER classification in M-AME and highlights the significance of molecular profiling in guiding treatment. The concurrent HRAS and PIK3CA mutations suggest potential targeted therapies, emphasizing the importance of a multidisciplinary approach. Further research is needed to establish standardized treatment guidelines for M-AME.https://doi.org/10.1007/s12672-025-02120-2AdenomyoepitheliomaPIK3CAHRAS Q61Estrogen receptorSanger sequencing |
| spellingShingle | Hung-Liang Pai Wei-Ting Hsu Chia-Chi Chang Ming-Hsin Yeh Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survival Discover Oncology Adenomyoepithelioma PIK3CA HRAS Q61 Estrogen receptor Sanger sequencing |
| title | Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survival |
| title_full | Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survival |
| title_fullStr | Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survival |
| title_full_unstemmed | Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survival |
| title_short | Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survival |
| title_sort | targeting malignant adenomyoepithelioma of the breast clinical insights on multimodal therapy and disease free survival |
| topic | Adenomyoepithelioma PIK3CA HRAS Q61 Estrogen receptor Sanger sequencing |
| url | https://doi.org/10.1007/s12672-025-02120-2 |
| work_keys_str_mv | AT hungliangpai targetingmalignantadenomyoepitheliomaofthebreastclinicalinsightsonmultimodaltherapyanddiseasefreesurvival AT weitinghsu targetingmalignantadenomyoepitheliomaofthebreastclinicalinsightsonmultimodaltherapyanddiseasefreesurvival AT chiachichang targetingmalignantadenomyoepitheliomaofthebreastclinicalinsightsonmultimodaltherapyanddiseasefreesurvival AT minghsinyeh targetingmalignantadenomyoepitheliomaofthebreastclinicalinsightsonmultimodaltherapyanddiseasefreesurvival |